PNH
PNH
Advertisement
Patrick DalyPNH | September 4, 2024
Lactate dehydrogenase level was pinpointed as a significant predictor of thromboembolism and mortality.
Read More
Andrew MorenoPNH | August 31, 2024
A multicenter, double-blind, randomized study found no clinically significant difference in efficacy or safety.
Andrew MorenoPNH | August 31, 2024
A post-hoc analysis evaluated results of the complement component 3-targeted therapy in patients from three clinical trials.
Andrew MorenoPNH | June 25, 2024
In PNH not previously treated with C5 inhibitors, crovalimab has shown efficacy noninferior to eculizumab.
Patrick DalyPNH | April 2, 2024
The US FDA has approved danicopan as an add-on therapy in patients with PNH and EVH on standard-of-care C5 inhibitor therapy.
Patrick DalyPNH | March 20, 2024
Iptacopan monotherapy improved hematologic and clinical outcomes of persistent anemia in patients with PNH.
Patrick DalyPNH | March 14, 2024
Dr. Griffin shares data from their real-world study on pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria.
Patrick DalyPNH | February 29, 2024
Danicopan as an add-on to C5 inhibitor therapy in patients with PNH with EVH showed sustained treatment benefits.
Patrick DalyPNH | February 6, 2024
The majority of newly diagnosed patients with PNH did not receive a PNH-specific therapy at diagnosis.
Patrick DalyPNH | January 25, 2024
Levels of lactate dehydrogenase significantly predicted fatigue and QOL in patients with PNH after C5 inhibitor therapy.
Patrick DalyPNH | January 10, 2024
Danicopan added to C5 inhibitor therapy led to significantly improved hemoglobin concentrations in patients with PNH.
Patrick DalyPNH | December 7, 2023
Pozelimab plus cemdisiran achieved intravascular hemolysis control in patients with paroxysmal nocturnal hemoglobinuria.
Patrick DalyPNH | November 27, 2023
The FDA has accepted the BLA for crovalimab, an investigational treatment for paroxysmal nocturnal hemoglobinuria.
Patrick DalyPNH | October 19, 2023
Iptacopan, a complement factor B inhibitor, was effective in patients with PNH with active hemolysis despite eculizumab use.
Rob DillardHematology | October 3, 2023
Take a look at these important studies relevant to anemia, venous thromboembolism, sickle cell disease, and PNH.
Cailin ConnerPNH | September 29, 2023
A study assessed survival and adverse events in patients with PNH treated with eculizumab.
Cailin ConnerPNH | September 15, 2023
Pegcetacoplan is a cost-effective alternative for the treatment of paroxysmal nocturnal hemoglobinuria.
Rob DillardPNH | September 8, 2023
The U.S. FDA has accepted a Biologics License Application for a novel drug to treat paroxysmal nocturnal hemoglobinuria.
Advertisement
Advertisement
Advertisement
Latest News

December 11, 2024